International Flavors & Fragrances Inc. (IFF), headquartered in New York, produces and markets cosmetic active and natural health ingredients for use in various consumer products. Valued at $21.3 billion by market cap, the company flavors and fragrances are individual ingredients and compounds of a large number of ingredients that are blended, mixed, and reacted together to produce proprietary formulas.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and IFF perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the specialty chemicals industry. IFF is a preeminent player in global flavors and fragrances, with 35,000+ products spanning food, beverage, personal care, and health & wellness. Its scale, innovation focus, and alignment with natural, sustainable, and customized ingredient trends support a competitive edge, while operations in 60+ countries provide access to emerging markets and evolving consumer preferences.
Despite its notable strength, IFF slipped 5.7% from its 52-week high of $89.32, achieved on Aug. 5. Over the past three months, IFF stock has gained 7.5%, outperforming the Dow Jones Industrials Average’s ($DOWI) marginal gains during the same time frame.
Shares of IFF have rose 25% on a YTD basis and climbed 30.9% over the past 52 weeks, outperforming DOWI’s YTD gains of 8.4% and 13.5% returns over the same time frame.
To confirm the bullish trend, IFF has been trading above its 200-day moving average since mid-January, with slight fluctuations. The stock has been trading above its 50-day moving average since early May, with minor fluctuations.
IFF has outpaced driven by strong growth in its Scent and Health & Biosciences divisions, solid volume recovery, and aggressive debt reduction. Investor sentiment has been bolstered by ongoing portfolio optimization including the strategic divestitures of its Food Ingredients and specialty natural ingredients units which freed up capital to pay down leverage and focus on high-margin core growth drivers.
On Aug. 4, IFF reported its Q2 results, and its shares closed up by 8.9% in the following trading session. Its adjusted EPS of $0.82 did not meet Wall Street expectations of $1.14. The company’s revenue was $2 billion, falling short of Wall Street forecasts of $2.7 billion. IFF expects full-year revenue in the range of $7.4 billion to $7.6 billion.
In the competitive arena of specialty chemicals, Givaudan SA (GVDNY) has lagged behind IFF, with a marginal downtick on a YTD basis and 8% losses over the past 52 weeks.
Wall Street analysts are reasonably bullish on IFF’s prospects. The stock has a consensus “Moderate Buy” rating from the 22 analysts covering it, and the mean price target of $94.44 suggests a potential upside of 12.1% from current price levels.
